On August 6, 2024, the Danish Health Data Authority opened the application period for changes in the 2026 DRG logic, including the creation of new DRG codes and changes in the grouping logic for existing DRGs. The deadline for the submission of the applications is November 8, 2024.

In August 2024, Dutch Organization for Health Research and Development (ZonMw) awarded four projects under the 2023 Round of the Care Evaluation and Appropriate Use program, including one project in orthopedics, one project on cardiovascular care, one project in cancer management and one project on urinary tract infection.

In July 2024, the National Institute for Health and Care Excellence (NICE) released a report on proposed approaches to the economic evaluation of multi-indication health technologies (MIHTs) developed by the HTA Lab. Examples of MIHTs include circulating tumor DNA tests, polygenic risk scores, and virtual ward platform technologies, which can be used across multiple disease areas or multiple indications. This report proposes approaches that NICE could adopt for future economic evaluations of MIHTs and provides recommendations for implementing the approaches on pilot topics.

On August 2, 2024, the French National Authority for Health (HAS) published a report presenting the program for evaluating targeted high-throughput sequencing procedures. The program defined indications for which the technology will be evaluated with a view to its transitioning to regular reimbursement under the Statutory Health

In July 2024, the National Institute for Health and Care Excellence (NICE) published one new Diagnostics Guidance (CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack) and one Technology Appraisal Guidance (Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma).

On August 7, 2024, the National Agency for Regional Health Services (AGENAS) announced a call for applications for Health Technology Assessment (HTA) for robotic surgery systems with intended use in the following surgical specialties: general surgery, gynecology and obstetrics, and urology, as part of the 2023-2025 National Health Technology Assessment Program for Medical Devices.

On August 2, 2024, the HAS published positive opinions on the inclusion of targeted high-throughput sequencing of gene panels in the medical management of lung cancer, gastrointestinal stromal tumors, and chronic lymphocytic leukemia in the NABM Nomenclature. This is a consequence of the efforts to disburden the innovation funding budget and clean the List of IVD tests outside the Nomenclature (Liste des actes hors nomenclatures, AHN, i.e., the merged 2023 RIHN List and the Supplementary List funded outside Statutory Health Insurance via the research and innovation budget).

On July 1, 2024, the annual call for proposals to the UK National Screening Committee (UK NSC) was launched. During the call, stakeholders can propose potential new screening topics or modifications of existing screening programs. The deadline for applications is September 30, 2024.

On July 1, 2024, the National Institute for Health and Disability Insurance (INAMI/RIZIV) introduced a new agreement (Convention), which allows permanent reimbursement for molecular biology tests by next-generation sequencing (NGS) in oncology and hemato-oncology. The tests were reimbursed temporarily in the context of the pilot Convention from 2019. Fifty-one new pseudo-nomenclature codes with tariffs were introduced. The pseudocode descriptions specify the indication, while certain biomarkers and reimbursement conditions are mentioned as notes to the code.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to better understand the potential scope of our support. From the week of the 12th of August, we are planning to work on 19 projects. Review the full list of planned activities in this post.

In July 2024, the UK National Screening Committee (UK NSC) released an annual report from April 1, 2023 to March 31, 2024. The report provides a summary of the Committee’s ongoing work and accomplishments, including recommendations regarding the introduction of national population screening programs.

At the end of July 2024, the French Ministry of Health released a document on the RIHN reform process, including the description on the new RIHN application and evaluation process, but also how the HAS will evaluate tests currently covered in the RIHN Nomenclature, with the purpose of of deciding whether these tests will be granted permanent reimbursement, or will be excluded from coverage within the statutory health insurance. Cleaning the current AHN List will allow for the financing of truly innovative tests patients need.